Abbott Laboratories (NYSE: ABT), headquartered in Abbott Park, Illinois, plans to unveil its financial performance for the fourth quarter before the market opens on Thursday, January 22. Analysts anticipate the company to report earnings per share (EPS) of $1.49 for the quarter, marking an increase from $1.34 recorded during the same period last year. In terms of revenue, the consensus estimate stands at $11.8 billion, up from $10.97 billion reported in last year's fourth quarter, as per Benzinga Pro data.
Adding to its recent strides, on January 20, Abbott obtained the CE Mark for its TactiFlex™ Duo Ablation Catheter, designed to treat patients experiencing abnormal heart rhythms. This approval allows the device to be marketed and used within the European Economic Area, signaling progress in Abbott's medical device portfolio.
Despite these positive developments, Abbott's shares saw a modest decline of 0.3% on Wednesday, closing at $120.73. This movement reflects a cautious trading environment ahead of the earnings announcement.
Examining the views of prominent equity analysts, several firms have commented on Abbott's stock and adjusted their outlooks accordingly. Bernstein analyst Lee Hambright reaffirmed an Outperform rating and raised the price target from $150 to $154 on January 9, 2026. Hambright's historical accuracy rate is noted at 60%.
Similarly, Barclays analyst Matt Miksic maintained an Overweight rating on Abbott and increased the price target from $162 to $169 as of January 5, 2026. Miksic's accuracy rate stands at 65%, indicating a strong track record in forecast precision.
From BTIG, analyst Marie Thibault kept a Buy rating intact with the price target fixed at $145, as of November 20, 2025. Thibault's accuracy is also recorded at 60%. Additionally, Raymond James analyst Jayson Bedford upheld an Outperform rating and adjusted the price target upward from $141 to $146 on October 16, 2025, corresponding with a 66% accuracy rate.
Contrasting these upward revisions, Evercore ISI Group's analyst Vijay Kumar retained an Outperform rating but lowered the price target slightly from $144 to $142 on the same October date, with an accuracy rate of 60%. This tempered adjustment introduces some nuance among analyst opinions.
Investors considering Abbott's stock may weigh these varying analyst perspectives, as each maintains a positive stance but differ in price expectations. The composite of their ratings reveals confidence in Abbott's potential but acknowledges the challenges ahead.
For investors monitoring trade opportunities, there is a focus on strategies that seek out high-probability setups in both rising and retreating markets. A highlighted approach that delivered significant gains in prior years exemplifies the kind of active trading environment surrounding stocks like Abbott.
Market metrics from Benzinga's Edge Rankings offer additional insight into Abbott's positioning. The stock exhibits momentum and quality scores in the mid-range, with value assessments indicating moderate attractiveness. Price trends are tracked over short, medium, and long terms to inform investment decisions.